Abdominal Transplantation

About Us

The Division of Abdominal Transplantation, under the direction of John A. Goss, M.D., the 19 faculty members and the staff of the division support adult and pediatric transplant programs that provide transplantation services across the Texas Medical Center at Baylor St. Luke’s Medical Center, Texas Children’s Hospital, and the Michael E. DeBakey VA Medical Center.


The Liver Transplant Fellowship at Baylor College of Medicine is an advanced surgical fellowship designed to train competent liver transplant surgeons during a two-year fellowship.


Learn about our transplant services.

The liver transplantation program is one of the busiest in the nation. Since 1998, surgeons have performed over 1,300 transplants with outstanding results. In 2012, 105 liver transplants were performed with one of the highest survival rates in the country. The adult one-year patient survival rate was 96 percent, versus the national average of 87 percent.

Pediatric cases counted for 40 of the 105 liver transplants performed, making this program at Texas Children’s the largest in the United States.

The pediatric one-year survival rate was 95 percent, compared to the national average of 88 percent.

The majority of adult kidney transplants take place at Baylor St. Luke’s Medical Center, where the one-year patient survival rate is 98 percent. Equally encouraging, the program’s pediatric one-year survival rate is 100 percent for patients cared for at Texas Children’s.

Given this track record of success, the division is now co-directing the Kidney Transplant Center at the Michael E. DeBakey VA Medical Center, one of only five VA centers to perform kidney transplantation for veterans.


Learn about abdominal transplantation research.

The division’s commitment to research, in part funded through National Institutes of Health grants and conducted at the Advanced Liver Therapies Research Center at Baylor St. Luke’s Medical Center, gives patients access to the latest clinical trials, including those testing therapies for chronic viral hepatitis B and C infections and treatments for thrombocytopenia in liver disease.